Stock Ratings / Health Care / MNOV / dividends

TENX (39) ZYBT (40) OSTX (42) RNXT (31) ⌘ Pro Terminal →

Medicinova Inc (MNOV) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.40 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.40

Medicinova Inc (MNOV) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $68.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MNOV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MNOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Medicinova Inc (NASDAQ: MNOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.40 (0.00% 1D, market cap $68.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MNOV ranks #854 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MNOV compare to TENX and ZYBT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNOV carries a Roarable E (30/100 RQD), trailing P/E of 5.7x, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MNOV?

▼

Per MNOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001226616), Medicinova Inc generated $409.7K in revenue, $12.0M in net income, and -$9.8M in free cash flow against $45.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.40 (-0.19%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNOV)Realized 20D OHLCV Swing Band: ±10.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY MNOV SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (33% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 38.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (±10.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.52-6.6% Next Q

Q2 (-2Q)

Grade E$1.42-2.1% Next Q

Q3 (-1Q)

Grade E$1.39+0.7% Next Q

Current

Grade E$1.40-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MNOV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MNOV currently carries a cautious 30/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.47) forces dealer call-delta covering toward $4.09.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNOV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MNOV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNOV)

✓Walkthrough of MNOV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MNOV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.72%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.42H $1.42L $1.38C $1.40VOL 29.7K

RES: $4.71SUP: $1.37SMA50: $1.79SMA200: $1.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNOV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MNOV Butterfly Map → + Track MNOV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-11.7%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MNOV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MNOV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MNOV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNOV)

Health Care Rank #854 of 1016 ⚔️ TENX vs MNOV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MNOV vs. TENX, ZYBT, OSTX, RNXT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Medicinova Inc (MNOV) ranks #854 by composite RQD confidence (30/100, grade E) and #709 by equity capitalization ($68.9M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with MNOV at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MNOV ACTIVE Medicinova Inc	E	30/100	5.7x	—	-35.0%	0.00%	$68.9M	Benchmark Subject
TENX Tenax Therapeutics Inc.	D-	39/100	—	—	-35.0%	-3.76%	$69.6M	/tenx-vs-mnov →
ZYBT Zhengye Biotechnology Holding Limited (Class A)	D-	40/100	—	20.5%	-22.3%	-9.09%	$67.8M	/zybt-vs-mnov →
OSTX OS Therapies Incorporated	D-	42/100	—	—	-35.0%	-4.61%	$67.6M	/ostx-vs-mnov →
RNXT RenovoRx Inc.	E	31/100	—	70.9%	-35.0%	-10.74%	$67.2M	/rnxt-vs-mnov →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001226616

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medicinova Inc (MNOV) reported GAAP revenue of $409.7K (N/A vs. FY2024 revenue of $0 , and -59.0% cumulative change since FY2023) , GAAP net income of $12.0M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (+7.8% YoY). On the balance sheet, MNOV closed FY2025 with $45.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$409.7K	$12.0M	-$9.8M	-$9.8M	$45.6M	—
FY2024 (FY)	2024-12-31	$0	$11.1M	-$10.6M	-$10.6M	$55.9M	—
FY2023 (FY)	2023-12-31	$1.0M	$8.6M	-$7.4M	-$7.4M	—	—

3. MNOV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MNOV compare to TENX and ZYBT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MNOV?

Where is MNOV trading relative to its 50-day, 200-day, and 52-week technical levels?

MNOV last traded at $1.40 (0.00% on volume of 29,687 shares), positioning the stock -21.79% below its 50-day simple moving average ($1.79) and -7.28% below its 200-day simple moving average ($1.51). Across its 52-week range of $1.22 to $3.90, MNOV sits at the 6.7% percentile with a 14-day RSI of 38.4 (NEUTRAL RANGE) and an implied next-earnings move of ±10.5% ($1.25 to $1.55).

MNOV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does MNOV pay a dividend and is it safe?

Medicinova Inc (MNOV) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: MNOV RQD Cockpit MNOV 12M Forecast MNOV Earnings & Move MNOV Dividends & DRIP MNOV Insiders & 13F MNOV Whale Options MNOV Profit Sankey MNOV News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MNOV — Medicinova Inc: What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1

As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Medicinova Inc (MNOV) carries a composite score of 30 / 100 (E — Roarable Strong Sell — Forensic Risk / Avoid).\n- Fundamental Cash Engine (1 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of -14.24% and gross margin of 0.0%.\n- Institutional 13F Whale Flow (7 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Pharmaceutical Preparations cohort.\n- Insider & Congressional Conviction (5 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (10 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (7 / 20): Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt-to-Equity of 0.50.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %	\n	---	---	---	---	---	---	---	---	---	---	\n	$1.40	$68.9M	5.7	5.3	N/A	0.24	0.00%	1.00	$1.22 - $3.90	-35.0%

Business & Sector Positioning

Medicinova Inc (MNOV) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Pharmaceutical Preparations with a market capitalization of $0.1B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Pharmaceutical Preparations (Health Care), MNOV exhibits an operating margin of -60.0% and net margin of 68.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (0.0%), and valuation discipline (5.3x forward P/E) relative to free cash flow conversion.

Open Questions for Prospective Investors

How sustainable is MNOV's current operating margin (-60.0%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (5.7x TTM P/E) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Pharmaceutical Preparations?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 0.20)?

MNOV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Medicinova Inc (MNOV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MNOV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 21d ago

MediciNova CEO Provides Shareholder Update

LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 21d ago

MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance

To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 27d ago

MediciNova to Participate in the Maxim Growth Summit

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 35d ago

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fat

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 35d ago

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova Inc (NASDAQ:MNOV) shares fell 14. 7% in premarket trading on Monday after the company reported topline results from a Phase 2 clinical trial evaluating tipelukast, or MN-001, in patients with nonalcoholic fatt

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 35d ago

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liv

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 35d ago

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fatLA JOLLA, Calif., Sept. 28, 2026 (G

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 39d ago

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MNOV Bull vs. Bear Conversation Board — What's Your Call at $1.40?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MNOV 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.23 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MNOV (E • RQD 30/100) a Buy at $1.40?

Welcome to the MNOV (Medicinova Inc) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.09 (-22.1%)

Spot @ $1.40

Pump the brakes on MNOV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MNOV, but look at what you are paying: 5.7x trailing P/E with tightening sector spreads. Unless Medicinova Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.61 (+15.0%)

Spot @ $1.40

MNOV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MNOV, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.40 (52-wk range $1.22 - $3.90), any beat on forward guidance forces shorts and underweight funds to chase.